Teacher Retirement System of Texas Increases Stock Position in Moderna, Inc. (NASDAQ:MRNA)

Teacher Retirement System of Texas boosted its holdings in Moderna, Inc. (NASDAQ:MRNA) by 14.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 101,382 shares of the company’s stock after purchasing an additional 12,651 shares during the quarter. Teacher Retirement System of Texas’ holdings in Moderna were worth $4,215,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. State Street Corp raised its holdings in shares of Moderna by 12.1% in the third quarter. State Street Corp now owns 16,847,212 shares of the company’s stock valued at $1,125,899,000 after buying an additional 1,823,276 shares during the last quarter. Geode Capital Management LLC raised its stake in Moderna by 2.6% during the 3rd quarter. Geode Capital Management LLC now owns 7,069,580 shares of the company’s stock valued at $470,670,000 after acquiring an additional 178,115 shares during the last quarter. Wellington Management Group LLP lifted its position in Moderna by 21.0% during the 3rd quarter. Wellington Management Group LLP now owns 5,224,685 shares of the company’s stock worth $349,166,000 after acquiring an additional 906,114 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in shares of Moderna by 0.5% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 3,890,812 shares of the company’s stock valued at $260,023,000 after purchasing an additional 19,819 shares during the last quarter. Finally, The Manufacturers Life Insurance Company increased its holdings in shares of Moderna by 6.2% in the third quarter. The Manufacturers Life Insurance Company now owns 3,073,934 shares of the company’s stock valued at $205,431,000 after purchasing an additional 178,939 shares during the period. Institutional investors and hedge funds own 75.33% of the company’s stock.

Analyst Upgrades and Downgrades

MRNA has been the subject of several recent research reports. UBS Group decreased their price target on Moderna from $96.00 to $78.00 and set a “buy” rating for the company in a report on Wednesday, February 19th. JPMorgan Chase & Co. lowered their target price on shares of Moderna from $40.00 to $33.00 and set an “underweight” rating on the stock in a report on Friday. Royal Bank of Canada reissued a “sector perform” rating and set a $40.00 price target on shares of Moderna in a report on Tuesday, February 18th. Evercore ISI set a $50.00 price objective on shares of Moderna in a research report on Friday, February 14th. Finally, Citigroup started coverage on Moderna in a research report on Thursday, March 13th. They set a “neutral” rating and a $40.00 target price on the stock. Four analysts have rated the stock with a sell rating, sixteen have given a hold rating, three have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Moderna has a consensus rating of “Hold” and a consensus target price of $59.00.

Moderna Price Performance

Shares of NASDAQ MRNA opened at $34.17 on Tuesday. The firm’s 50-day moving average is $34.89 and its two-hundred day moving average is $45.39. The company has a market capitalization of $13.21 billion, a PE ratio of -3.68 and a beta of 1.86. Moderna, Inc. has a 12-month low of $29.25 and a 12-month high of $170.47.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.